Department of Clinical Pharmacology & Cancer Center, ZhongShan Hospital, Fudan University, Shanghai, People's Republic of China.
Department of Pharmacy, Shanghai Children's Medical Center, School of Medicine, Shanghai JiaoTong University, Shanghai, People's Republic of China.
Drug Des Devel Ther. 2023 Mar 10;17:761-769. doi: 10.2147/DDDT.S388846. eCollection 2023.
This study aimed to investigate the effect of food on the pharmacokinetics and safety profiles of SCC244, a novel oral c-Met inhibitor in healthy Chinese male subjects.
It was a randomized, open-label, and 3-period crossover design, single-dose phase I clinical trial. A total of 18 healthy male subjects were enrolled. These subjects received a single oral 300 mg dose of SCC244 with a 14-day washout between each period. Blood samples were collected at the designated time points and determined using a validated liquid chromatography tandem mass spectrometry method. Pharmacokinetic parameters were calculated by noncompartmental methods. Tolerability was assessed by physical examination, vital sign measurements, 12-lead ECG, clinical laboratory tests, and adverse events (AEs) monitoring throughout the study.
Eighteen eligible subjects were enrolled in the study. The ratios (90% CI) of C values for SCC244 in high-fat and low-fat meal states to that observed in fasted state were 194.8% (174.3-217.7%) and 194.6% (174.1-217.5%), respectively. The ratios of AUC and AUC in the high-fat meal state versus the fasted state were 237.4% (208.7-270.0%) and 235.9% (207.5-268.3%), respectively. The ratios of AUC and AUC in the low-fat meal state versus the fasted state were 219.2% (192.7-249.3%) and 218.3% (192.0-248.3%), respectively. Median T values and mean t were similar in all groups. The most common AEs were headache, blood fibrinogen decreased, head discomfort, dizziness, and protein urine presence. All AEs were Common Terminology Criteria for Adverse Events (CTCAE) grade 1 (except 1 case of grade 2) and have resolved by the end of the study.
The bioavailability of the tablet formulation of SCC244 was significantly increased when administered with high- and low-fat meals. However, the meals did not affect the median T and t. Safety under different fed conditions was comparable to fasted conditions in this study.
本研究旨在探讨食物对新型口服 c-Met 抑制剂 SCC244 在健康中国男性受试者中的药代动力学和安全性特征的影响。
这是一项随机、开放标签、三周期交叉设计的单次剂量 I 期临床试验。共纳入 18 名健康男性受试者。这些受试者接受单次口服 300mg SCC244 剂量,每个周期之间有 14 天的洗脱期。在指定时间点采集血样,并采用经过验证的液相色谱串联质谱法进行测定。采用非房室法计算药代动力学参数。通过体格检查、生命体征测量、12 导联心电图、临床实验室检查和整个研究期间的不良事件(AE)监测来评估耐受性。
本研究共纳入 18 名符合条件的受试者。高脂肪和低脂肪餐状态下 SCC244 的 C 值比值(90%CI)分别为 194.8%(174.3-217.7%)和 194.6%(174.1-217.5%)。高脂肪餐状态下 AUC 和 AUC 的比值分别为 237.4%(208.7-270.0%)和 235.9%(207.5-268.3%)。低脂肪餐状态下 AUC 和 AUC 的比值分别为 219.2%(192.7-249.3%)和 218.3%(192.0-248.3%)。所有组的中位 T 值和均值 t 相似。最常见的 AE 是头痛、血纤维蛋白原降低、头部不适、头晕和蛋白尿阳性。所有 AE 均为不良事件通用术语标准(CTCAE)分级 1(除 1 例为 2 级),并在研究结束时已解决。
SCC244 片剂制剂与高脂肪和低脂肪餐同时给药时,其生物利用度显著增加。然而,这些膳食并未影响中位 T 和 t。在本研究中,不同进食条件下的安全性与禁食条件相当。